KALA BIO, Inc. (KALA)
| Market Cap | 3.72M -64.6% |
| Revenue (ttm) | n/a |
| Net Income | -10.08M |
| EPS | -1.30 |
| Shares Out | 19.34M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 860,501 |
| Open | 0.1903 |
| Previous Close | 0.1880 |
| Day's Range | 0.1720 - 0.2051 |
| 52-Week Range | 0.1146 - 95.5000 |
| Beta | -2.41 |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Nov 18, 2026 |
About KALA
KALA BIO, Inc., a biopharmaceutical company, engages in the development of an on-premises artificial intelligence (AI) infrastructure platform for biotechnology research applications in the United States. The company develops Researgency, an agentic AI research platform for private enterprise AI deployment. Its platform intends to utilize the KPI-012 clinical development dataset as a proof-of-concept validation environment, as well as the mesenchymal stem cell secretome (MSC-S) and persistent corneal epithelial defects (PCED) research for agent... [Read more]
Financial Performance
Financial StatementsNews
KALA Bio Signs Non-Binding LOI to Acquire Nationwide Telehealth Platform with Approximately $48 Million in Sales Since Inception
Proposed Acquisition Valued at Approximately $15 Million Would Add an Established 50-State Telehealth Business, with over 90,000 clients, Focused on Peptides such as GLP-1 Weight Management, Hormone H...
KALA BIO Proxy statement: Proxy filing
KALA BIO filed a proxy statement on September 24, 2026, providing details for shareholder voting and corporate governance matters.
Kala Bio, Virotek sign letter of intent with U.S. DNA testing platform
Kala Bio (KALA) and Virotek announced that they have signed a non-binding letter of intent with a U.S. DNA testing platform under which the platform would resell Virotek’s selected suite…
Kala Bio and Virotek Sign Letter of Intent with U.S. DNA Testing Platform to Resell Virotek's Suite of Genetic Testing Products
Agreement would expand the companies' genetic testing collaboration beyond ophthalmology to a selected suite of genomic testing products through an additional U.S. reseller channel Agreement would exp...
KALA BIO Adds Healthcare Operator Yenvy Truong to Advisory Team
Founder of The LSM Group to support KALA's growth across its existing business and potential acquisitions Founder of The LSM Group to support KALA's growth across its existing business and potential a...
KALA BIO Proxy statement: Proxy filing
KALA BIO filed a proxy statement on September 11, 2026, providing details for shareholder voting and corporate governance matters.
Kala Bio, Virotek announce exclusive distribution and reseller agreement
Kala Bio (KALA) and Virotek announced that they have finalized a definitive exclusive distribution and reseller agreement and related quality, brand, and data protection agreements. Under the agreemen...
Kala Bio and Virotek Finalize Definitive Agreement Establishing Exclusive U.S. Distribution Partnership for Ophthalmology Genetic Testing Program
Agreement Grants Kala Exclusive U.S. Rights to Market and Distribute Virotek's Ophthalmology Genomic Testing Program Agreement Grants Kala Exclusive U.S. Rights to Market and Distribute Virotek's Opht...
Kala Bio, Virotek enters LOI for distribution agreement
Kala Bio (KALA) and Virotek announced that they have entered into a letter of intent outlining the principal terms under which the companies intend to negotiate a definitive agreement appointing…
Kala Bio and Virotek Announce Letter of Intent to Establish an Exclusive U.S. Distribution Partnership for Ophthalmology Genetic Testing Program
ARLINGTON, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Kala Bio, Inc. (Nasdaq: KALA) ("Kala") and Virotek Inc. ("Virotek"), a CLIA-registered precision health and clinical genomics company, today announ...
KALA BIO Quarterly report: Q2 2026
KALA BIO has published its Q2 2026 quarterly earnings report on August 19, 2026.
KALA BIO Registration statement: Registration filing
KALA BIO filed a registration statement on June 12, 2026, providing details about a securities offering with the SEC.
KALA BIO Quarterly report: Q1 2026
KALA BIO has published its Q1 2026 quarterly earnings report on May 15, 2026.
Kala Bio files $350M mixed securities shelf
17:27 EDT Kala Bio (KALA) files $350M mixed securities shelf
Kala Bio announces reverse stock split
Kala Bio (KALA) announced that it intends to effect a reverse stock split of its common stock at a ratio of 1 post-split share for every 50 pre-split shares. The…
KALA BIO Announces Reverse Stock Split
ARLINGTON, Mass., May 07, 2026 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ: KALA) (“KALA BIO” or the “Company”), today announced that it intends to effect a reverse stock split of its common stock, par...
KALA BIO Registration statement: Registration filing
KALA BIO filed a registration statement on May 7, 2026, providing details about a securities offering with the SEC.
Kala Bio ‘celebrates’ U.S. Executive Order for psychedelic medicine
KALA BIO (KALA) “celebrated the landmark Executive Order” signed by U.S. President Donald Trump on April 18, 2026. The Order directs the FDA to prioritize the review of psychedelic compounds,…
Kala Bio Celebrates Trump Executive Order as Game-Changer for Psychedelic Medicine
ARLINGTON, Mass., April 21, 2026 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ: KALA) (“KALA” or the “Company”) today celebrated the landmark Executive Order signed by U.S. President Donald J.
KALA BIO Annual report: Q4 2025
KALA BIO has published its Q4 2025 annual report on April 15, 2026.
Kala Bio Engages Dr. Saeid Babaei as Senior Scientific Advisor to Evaluate Clinical Assets and Precision Development Opportunities
Engagement will assess KALA's clinical assets, development options, and AI-enabled analytical opportunities, including the MSC Secretome platform Engagement will assess KALA's clinical assets, develop...
KALA BIO Delivers Industry-Leading AI Infrastructure: Bionic Intelligence Research Agent Now Live
Next-Generation Agentic AI Platform Achieves Live Enterprise Deployment, Delivering Secure, Scalable, Autonomous Research Solutions to Global Biotechnology and Pharmaceutical Organizations Next-Genera...
Red Light Holland engages Kala Bio with its Researgency.ai platform
Red Light Holland and Kala Bio (KALA) announced that Red Light has engaged Kala Bio’s with its Researgency.ai agentic artificial intelligence platform under world wide license from Younet to support…
Red Light Holland Engages Kala Bio's Researgency.AI Platform to Support Clinical Development of Filament's Patented PEX010 Botanical Psilocybin Drug Candidate
AI-powered autonomous research agents to be deployed in support of PEX010 clinical development strategy, leveraging Kala Bio's purpose-built agentic AI platform for the biotechnology industry TORONTO ...